BIOMAT Database Logo BIOMAT Database Logo

Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. 1997

A Ohara, and S Kojima, and N Hamajima, and M Tsuchida, and S Imashuku, and S Ohta, and H Sasaki, and J Okamura, and K Sugita, and H Kigasawa, and Y Kiriyama, and J Akatsuka, and I Tsukimoto
Aplastic Anemia Committee of the Japanese Society of Pediatric Hematology.

The improved outcome of acquired aplastic anemia (AA) has revealed later complications, such as myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). We retrospectively analyzed 167 children with severe acquired AA. Eleven of 50 children treated with cyclosporin (CSA) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) developed MDS/AML; 8 of these were within 36 months of the diagnosis of AA, much earlier than previous reports. Six of the 11 children received rhG-CSF exceeding 10 microg/kg/d, and 9 received rhG-CSF therapy for over 1 year. Ten children showed monosomy 7 at diagnosis of MDS. All of the 11 children were administered both CSA and rhG-CSF. There was no development of MDS/AML among 41 children treated with either CSA or rhG-CSF or among 48 children who underwent bone marrow transplantation. A well-controlled clinical trial is warranted to determine whether therapeutic modalities affect the development of MDS/AML in children with severe acquired AA.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007223 Infant A child between 1 and 23 months of age. Infants
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D008297 Male Males
D009006 Monosomy The condition in which one chromosome of a pair is missing. In a normally diploid cell it is represented symbolically as 2N-1. Monosomies
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children

Related Publications

A Ohara, and S Kojima, and N Hamajima, and M Tsuchida, and S Imashuku, and S Ohta, and H Sasaki, and J Okamura, and K Sugita, and H Kigasawa, and Y Kiriyama, and J Akatsuka, and I Tsukimoto
Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.
March 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
A Ohara, and S Kojima, and N Hamajima, and M Tsuchida, and S Imashuku, and S Ohta, and H Sasaki, and J Okamura, and K Sugita, and H Kigasawa, and Y Kiriyama, and J Akatsuka, and I Tsukimoto
CD4+ T-Cell Subsets in Aplastic Anemia, Myelodysplastic Syndrome, and Acute Myelogenous Leukemia Patients: a Comparative Analysis.
July 2023, Clinical laboratory,
A Ohara, and S Kojima, and N Hamajima, and M Tsuchida, and S Imashuku, and S Ohta, and H Sasaki, and J Okamura, and K Sugita, and H Kigasawa, and Y Kiriyama, and J Akatsuka, and I Tsukimoto
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
July 2020, Blood,
A Ohara, and S Kojima, and N Hamajima, and M Tsuchida, and S Imashuku, and S Ohta, and H Sasaki, and J Okamura, and K Sugita, and H Kigasawa, and Y Kiriyama, and J Akatsuka, and I Tsukimoto
[Development of myelodysplastic syndrome and leukemia in children with acquired anemia].
May 2000, [Rinsho ketsueki] The Japanese journal of clinical hematology,
A Ohara, and S Kojima, and N Hamajima, and M Tsuchida, and S Imashuku, and S Ohta, and H Sasaki, and J Okamura, and K Sugita, and H Kigasawa, and Y Kiriyama, and J Akatsuka, and I Tsukimoto
[Acute myelogenous leukemia. Associated with oxyphenbutazone induced aplastic anemia].
August 1974, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
A Ohara, and S Kojima, and N Hamajima, and M Tsuchida, and S Imashuku, and S Ohta, and H Sasaki, and J Okamura, and K Sugita, and H Kigasawa, and Y Kiriyama, and J Akatsuka, and I Tsukimoto
[Acquired aplastic anemia developing myelodysplastic syndrome/acute myeloid leukemia: clinical analysis of nineteen patients and literatures review].
March 2015, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
A Ohara, and S Kojima, and N Hamajima, and M Tsuchida, and S Imashuku, and S Ohta, and H Sasaki, and J Okamura, and K Sugita, and H Kigasawa, and Y Kiriyama, and J Akatsuka, and I Tsukimoto
Clonal hematopoiesis in acquired aplastic anemia.
July 2016, Blood,
A Ohara, and S Kojima, and N Hamajima, and M Tsuchida, and S Imashuku, and S Ohta, and H Sasaki, and J Okamura, and K Sugita, and H Kigasawa, and Y Kiriyama, and J Akatsuka, and I Tsukimoto
[Clinical course of severe acquired aplastic anemia to myelodysplastic syndrome and acute leukosis].
July 1995, Medicina clinica,
A Ohara, and S Kojima, and N Hamajima, and M Tsuchida, and S Imashuku, and S Ohta, and H Sasaki, and J Okamura, and K Sugita, and H Kigasawa, and Y Kiriyama, and J Akatsuka, and I Tsukimoto
Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome.
November 2011, American journal of hematology,
A Ohara, and S Kojima, and N Hamajima, and M Tsuchida, and S Imashuku, and S Ohta, and H Sasaki, and J Okamura, and K Sugita, and H Kigasawa, and Y Kiriyama, and J Akatsuka, and I Tsukimoto
Clonal hematopoiesis in patients with acquired aplastic anemia.
December 1991, Blood,
Copied contents to your clipboard!